









PURIFICATION AND SOME PROPERTIES OF AN ALKALINE PROTEASE 
FROM RAT SKELETAL MUSCLE 
Thesis presented by 
BENJAMIN BOSCH 
in fulfilment of the requirements for the degree of 




FACULTY OF MEDICINE 
UNIVERSITY OF CAPE TOWN 











The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 











Normal rat skeletal muscle (Bismarck Brown stain) showing 
muscle fibres containing nuclei, with connective tissue 




Various alkaline proteases derived from skeletal muscle have been des-
cribed by a number of researchers and have been purified to varying 
degrees. Such alkaline proteases may play an important role in the 
metabolism of myofibrillar and other muscle proteins and as such 
deserve to be fully characterised. 
In this study, a major myofibrillar alkaline protease was purified from 
rat skeletal muscle. The enzyme degraded both denatured casein and 
azocasein and had a pH optimum of 9,0. The molecular mass was 32 250 + 
650. The presence of a second, minor alkaline protease was demonstrated 
using three different separation techniques as well as by inhibitor 
studies. 
The major protease was insensitive to inhibition by pepstatin and leu-
peptin, whilst 90% of the activity was expressed in the presence of 
2 mM EGTA. A moderate degree of inhibition was observed in the presence 
of soybean trypsin i'nhibitor and the protease was markedly sensitive to 
chymostatin. A similar alkaline protease was partially pµrified from 
rat cardiac muscle using the same purification procedure. 
Incubation of washed myofibrils in the presence of sodium pyrophosphate 
released a factor into·the supernatant,the removal of which facilitated 
the separation of myofibrillar alkaline protease from the myofibrils. 
The factor appeared to be necessary for binding of the alkaline protease 
to the myofibrillar proteins but its removal did not disrupt the binding 
of proteolytic activity already attached to the myofibrillar proteins . 
• 
i i 
An inhibitor of myofibrillar alakline protease was demonstrated which is, 
in principle, capable of playing an important regulatory role in con-
trolling the activity of these enzymes and thereby of myofibrillar 
protein catabolism . 
iii 
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ABBREVIATIONS 
A - absorbance 
Ac - acetyl 
Ala - alanine 
Arg - arginine 
Bz - benzyl 
C - Celsius 
CM - carboxymethyl 
cm - centimetre 
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em - emission 
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ex excitation 
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h - hour 
LSB - low salt buffer 
M - molar 
mA - mi 11 i amps 
MAP myofibri11ar alkaline protease 
mCi - mi11icurie (3,7 x 10
7 disintegrations/second} 
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CHAPTER 1 
INTRODUCTION 
1 .1. GENERAL PROTEIN DEGRADATION 
Proteins are the most prevalent "building blocks of the cell
11 and 
generally constitute about 75% of dry cell mass. The majority of these 
macromolecules are not, however, purely structural components and most of 
them play important functional roles in cellular metabolism. Proteins 
are thus enzymes, regulatory elements, contractile systems, and membrane 
carriers, to name just a few. Generally, steady-state nett amounts of 
each of these proteins in a particular cell area function of the balance 
between protein synthesis and degradation. 
The anabolic pathway has been actively studied for a number of years and 
the biosynthesis of proteins is thus quite well understood, from the in-
formational role of DNA to the synthesis of polypeptide chains by ribo-
somes. The rates of .synthesis of various proteins, in intact-cell systems, 
and the effects of various stress conditions, have also been measured and 
assessed. In contrast, the importance of protein degradation has only 
been established during the last decade as a result of the appreciation 
that the control of protein degradation may be important in determining the 
levels of a number of specific proteins in the cell (Katunuma, 1977). Thus 
the cellular concentrations of specific functional proteins may be con-
trolled by the activities of various specific proteases, and these latter 
enzymes may also mediate protein degradation in general. 
Intracellular proteases may not only play an important physiological role 
but may also be involved in pathological processes. Elevated levels of 
muscle proteases have been observed in various pathological states, such 
2 
as cachexia (Mayer et al, 1976), denervation (Goldspink, 1976), myopathy 
(Katunuma et al, 1977), diabetes (Rithig et al, 1975, 1978) and starvation 
(Mayer et al, 1974). The degradation of proteins in these states can be 
seen to be 11 controlled 11 (as in starvation to provide energy) or may be 
11 uncontrolled 11 (as in cachexia). Proteases also act as controllers/ 
activators in many physiological reactions outside cells, e.g. blood coag-
ulation-fibrinolysis, blood pressure control by the renin-angiotensin 
system and complement activations, while known intracellular processes 
involving proteolysis are hormone and enzyme processing and intracellular 
digestion of endocytosed proteins. 
Many proteases in these systems act specifically. In order to understand 
the regulation of protein degradation in healthy and/or diseased tissues, 
the various proteases involved have to be fully characterised so that the 
precise contribution of each protease in complex processes can be assessed. 
Lindestrom-Lang (1952) defined two types of proteolysis - the 11 one-by-one 11 
and the 11zipper 11 types of reaction. Zipper-attack is characteristic of 
zymogen activation and limited proteolysis, in which a stable derivative 
is formed. In general it is likely that the initial cleavage of native 
proteins during intracellular protein degradation occurs by limited 
proteolysis. This need not be the first "step" in the process, however. 
Thus, protein degradation may consist of three major steps: the initial 
and possibly rate-limiting stage involves the transformation of. the 
protein into a form susceptible to proteases. This may depend on changes 
in the nature of the peptide bonds which are exposed, conformational 
changes induced by such factors as the absence of co-enzymes, substrates, 
and allosteric effectors, by covalent modifications and by the extent to 
































































































































































factors which greatly influence the catabolic rates of enzymes have been 
examined by many researchers (Goldberg and Dice, 1974; Schimke, 1975; 
Kominami et al, 1975; Katunuma, 1975 and Katunuma et al, 1976). For 
example, the conversion from the holo- to apo-form in the case of orni-
thine aminotransferase was shown by Katunuma to be accompanied by a con-
formational change in the molecule, which probably renders the enzyme 
more susceptible to group-specific proteases. 
The second stage of protein degradation may involve limited proteolysis 
related to the selective specificity of certain groups of enzymes. Such 
a mechanism may involve a variety of group-specific proteases for all the 
proteins in the eel l . However, although a few group-specific proteases 
have been reported, they are still not numerous (Bonsignore et al, 1968; 
Katunuma et al, 1971). An additional possible mechanism for the second 
step was implied by Prouty et al (1975), who found that the presence of 
amino acid analogues in proteins during the degradation of abnormal 
proteins in Escherischia coli, decreased their solubility, so that intra-
cellular inclusions were formed by the spontaneous precipitation of the 
abnormal proteins. rhey proposed that the spontaneous aggregation of 
abnormal proteins serves to promote their recognition by the degradative 
system. Such a mechanism was also proposed by Ballard and Hopgood (1974) 
for the degradation of phosphoenolpyruvate carboxykinase .i!!. vitro and in 
vivo; they suggested that the enzyme may be denatured and precipitated 
before being attacked by the protease (Haider and Segal, 1972). 
The third stage of degradation presumably involves the further degradation 
of the intermediates formed by limited proteolysis since the final out-
come seems to be the formation in the cell of free amino acids. Less 
specific proteases may be active in· this process, possibly lysosomal 
5 
cathepsins. This would require the translocation of the intermediate 
products into lysosomes. However, it is not yet clear whether proteins 
or fragments are translocated into intact lysosomes. 
Lysosomes are a major focus of proteases in the cell. Neely and Morti-
more (1974) found most of the proteolytic activity to reside in the 
lysosomal-mitochondrial fraction upon assaying the endogenous proteolytic 
activity of the sub-cellular fractions of perfused rat liver. De Duve 
and Wattiaux (1966) reported the presence ·of lysosomes in virtually all 
cells. Numerous acidic hydrolases (or cathepsins) are contained in the 
lysosomes and inactivate or digest several native enzymes or proteins 
under acidic conditions. Alanine aminotransferase (Segal et al, 1969; 
Haider and Segal, 1972) and tyrosine aminotransferase (Auricchio et al, 
1972) are inactivated at pH 5 by the mitochondrial-lysosomal fraction 
from rat liver. Johnson and Velich (1972) reported that glyceraldehyde-
3-phosphate dehydrogenase and aldolase are inactivated at pH 6,5 by a 
mitochondrial-lysosomal fraction from rabbit liver. Huisman et al (1973) 
showed that thiol-cathepsins hydrolyse · native proteins,including cytochrome 
C, ribonuclease and horse-radish peroxidase,at pH 5. However, in all 
these cases it was necessary to rupture the lysosomes to allow the cathep-
sins to react with the proteins. It would thus appear_ that a certain 
amount of initial protein degradation has to occur in the cytosol before 
the enzyme/protein is able to enter lysosomes, where the cathepsins can 
degrade them to completion. Numerous other intracellular proteases have 
now also been found (for example from rat liver, intestine, heart and 
skeletal muscle) which are active at neutral to alkaline pH and which 
cleave protein substrates by limited or complete proteolysis (Kominami 
et al, 1972; Katunuma, 1973 a,b; Katunuma et al, 1973, 1975). 
6 
1 .2. MYOFIBRILLAR AND OTHER NON-LYSOSOMAL PROTEASES IN MUSCLE CELLS 
Some of these neutral and alkaline proteases are associated in frac-
tionated tissue preparations with the contractile proteins which they 
can degrade in vitro (Bhan et al, 1978; Rothig et al, 1975; Sanada 
et al, 1978; Yasogawa et al, 1978). Others have been found in both 
the 11 organellar 11 and 11 soluble 11 fractions of the cell (see below). 
The soluble proteases comprise at least three separable enzyme types: 
(a) a Ca+2-activated protease, which removes Z-lines from myofibrils, 
irreversibly activates muscle phosphorylase kinase, is widely dis-
tributed in other tissues and is eluted from a DEAE-cellulose 
column by 0,25 M NaCl (Busch et al, 1972; Dayton et al, 1976; 
Ishiura et al, 1978); 
(b) an alkaline protease, which has been partially purified from rat 
skeletal muscle, hydrolyses endogenous muscle protein and N-acetyl-
L-tyrosine ethyl ester and is inhibited by metal ions, including 
Ca+2 (Koszalka and Miller, 1960); and 
(c) a sulphydryl-dependent neutral protease that degrades insulin but 
not pro-insulin (Duckworth et al, 1972). 
The particulate proteases include: 
(a) a 11myofibrillar 11 protease (MAP) from heart and skeletal muscle 
(Bhan et al, 1978; Griffin and Wildenthal, 1978; Mayer et al, 
1974); and 
(b) serine proteases from heart and skeletal muscle that hydrolyse 
substrates of chymotrypsin and are inhibited by soybean trypsin 
inhibitor (Sanada et al, 1978, 1978; Hasogawa et al, 1978). 
7 
It has been suggested that these enzymes specifically inactivate 
the apoproteins of many pyridoxal-requiring enzymes ("group-
specific protease"). 
1 .3. THE PROBLEMS OF THE NATURE AND IDENTITY OF MYOFIBRILLAR ALKALINE 
PROTEASES (MAP) 
The alkaline particulate or 11myofibril-associated 11 proteases have 
properties that are rather similar to those of the alkaline serine 
protease(s) of peritoneal mast cells (Noguchi and Kandatsu, 1976) and 
the activity of the "skeletal muscle enzyme" is markedly reduced by 
the treatment of rats with Compound 48/80, a mast cell degranulator. 
Using fluorescent antibodies, a serine protease of skeletal muscle has 
also been localised to mast cells and shown to be structurally identical 
to the chymotrypsin-like enzymes of mast cells (Woodbury et al, 1978a,b). 
In regard to the particulate alkaline proteases (pH 7,8) of rat hearts, 
that will degrade protein to free amino acids, at least 90% of this 
activity appears to be localised to mast cells (McKee et al, 1979). 
These findings cast a serious doubt on the putative role of the proteases 
which are found associated with myofibrils, presumably artefactually in 
skeletal muscle preparations. 
Katunuma and Kominami (1977) found that the group-specific alkaline 
proteases catalyse a limited proteolysis, with considerable specificity; 
this specificity differed for various substrates. Incubation of the 
apo-form of ornithine aminotransferase with crystalline protease from 
the muscle layer of the small intestine indicated that the inactivating 
reaction was associated with limited proteolysis, as only a few peptides 
and a small amount of ninhydrin-reactive material was released, even 
8 
with a total loss of aminotransferase activity. The high molecular 
weight product was found to have a molecular mass very similar to that 
of the native enzyme on PAGE. The protease split each subunit to form 
polypeptide chains of molecular weight 27 000 (Fragment A) and 13 000 
(Fragment B). Fragments A and B eluted together on a Sephadex G-100 
column, suggesting that the cleavage products remain associated unless 
the protein is cleaved. On Ouchterlony double-diffusion analysis, 
the binding affinity for pyridoxal phosphate (1/dimer unit) and the 
spectral characteristics (A420;A280 ) were the same between apo-enzyme 
and product. However, the product had completely lost enzymic 
activity and the capacity to polymerise an addition of pyridoxal phos-
phate. Binding affinity for co-enzyme and antibodies, the exposure of 
thiol groups, tyrosine and tryptophan residues, the apparent tertiary 
structure of the product (compared with native apo-ornithine trans-
aminase) were all not changed by limited proteolysis (Kominami et al, 
1975). In contrast, after denaturation of the apo-ornithine trans-
aminase in 8 M urea, a random proteolysis by group-specific proteases 
was observed. 
Rat liver cystathionase catalyses several different enzymic reactions 
(Pascal et al, 1972) and is composed of eight apparently identical 
subunits . Incubation of the apo-form of crystallised cystathionase 
from rat liver with group-specific proteases from the muscle layer of 
small intestine at o0 c resulted in the splitting of each subunit to 
form an enzymatically inactive polypeptide chain of molecular weight 
38 000. Upon continued incubation, the protein band of molecular 
weight 38 000, which accumulated during the initial stages, disappeared 
completely. The 38 000 molecular weight product was completely devoid 
of enzymic activity. SOS-PAGE indicated that limited proteolysis was 
9 
accompanied by dissociation of the four subunits which constitute the 
native cystathionase enzyme. The initial proteolytic product thus 
appears to be more susceptible to proteolysis than the native apo-
cystathionase. 
Two important differences are apparent between the hydrolysis of 
ornithine aminotransferase and rat liver cystathionase, namely -
(l} limited proteolysis was accompanied by dissociation of the subunits 
in the one case and not in the other; and 
(2) the stability of the peptide fragments formed by limited proteolysis 
differed. 
The reason for these differences in the course of proteolysis is thought 
to rest with differences in their conformation, as Kominami et al (1975) 
showed that a conformational contribution is also important in the 
difference in susceptibility of the holo- and apo-forms of pyridoxal 
enzymes to group-specific proteases. Matsuda and Fischer (1975) re-
ported that a group-specific protease split each subunit of muscle 
phosphorylase b (MW 100 000) by limited proteo"lysis, forming two frag-
ments of molecular weight 60 000 and 36 000. Thus alkaline proteases 
have the potential to cause specific and selective degradation of 
proteins to produce products which may be more susceptible to general 
proteolysis. It can be concluded that alkaline proteases are poten-
tially capable of playing an important regulatory role in protein 
degradation.!.!!. vivo and warrant further detailed investigation in order 
to evaluate the role played by such enzymes in the protein metabolism 
of muscle cells. 
10 
Numerous proteolytic enzymes present in muscle tissue, each with 
optimum activity in the alkaline pH range, have been described to date, 
but they have generally been poorly defined and their possible identity 
or non-identity has not been established. Koszalka and Miller (1960a,b) 
have described a cytoplasmic alkaline protease in rat skeletal muscle, 
which has been partially purified by ammonium sulphate precipitation. 
These authors suggested that their enzyme is involved in the turnover 
of myofi bril s, and this was a 1 so proposed for . the chymotryps i n-1 i ke 
enzyme purified by Noguchi and Kandatsu (1971). A similar enzyme has 
been described by Holmes et al (1971) and more recently by Drabikowski 
et al (1977). It is likely that all these activities originate in 
mast cells and are released by homogenisation (Park et al, 1973; Noguchi 
and Kandatsu, 1976; Drabikowski et al, 1977). In an attempt to localise 
the alkaline proteolytic activity, Pennington and co-workers subjected 
muscle homogenates to differential and density-gradient centrifugation. 
They found that "the enzyme is either attached to a cell fragment which 
sediments with the myofibrils or has become adsorbed on the latter" 
(Park et al, 1973). Mayer et al (1974) have described some ·properties 
and adaptive changes of the rat myofibr1llar protease under varying 
conditions affecting the rates of muscle protein degradation, although 
it is still not clear whether the alkaline proteolytic activity 
measured arose from one or several distinctive enzymes (Pennington, 
1977). The proteases have generally not been completely purified but 
have been compared in terms of similarities and differences between 
properties of the enzymes. Some of these differences may be attribut-
able to the presence of contaminants which may mask certain properties 
of the enzymes. Additional experiments are clearly needed to show 
whether the observed differences result from the presence of various 
impurities or whether in rat skeletal muscle there exist discrete 
11 
classes of alkaline proteases (Dahlmann and Reinauer, 1978). 
Dahlmann and Reinauer (1978) purified an alkaline protease from rat 
skeletal muscle. The muscle was homogenised in a buffer at pH 8,5 
containing 1 M KCl and was stirred for 12 hours. After centiifuging 
for 30 min, the enzyme was present in the 15 000 g supernatant. 
Ammonium sulphate was then added to the supernatant to give a ·solution 
33% saturated with respect to the salt, and after centrifuging (15 000 g; 
15 min), the protease was recovered in the precipitate. This precipi-
tate was soluble only in buffer containing at least 0,6 M KCl, which 
strongly suggests that proteins of the actin-myosin complex constitute 
the main part of this sediment. The enzyme could not be separated 
from the myofibrillar proteins by mechanical stirring nor by treatment 
with Triton X-100, but it was invariably co-solubilised at high concen-
trations of KCl. The viscosity of the solution was lowered by incuba-
ting _it with trypsin coupled to Sepharose-48 (37°c for 30 minutes) and 
then removing the coupled trypsin-Sepharose-48 by centrifugation and 
filtration. The enzyme was further purified by chromatography on 
soybean trypsin inhibitor-Sepharose, followed successively by DEAE-
Sephadex A-50 and Sephadex G-75. The purified myofibrillar protease 
migrated as a single protein band on polyacrylamide-gel micro-disc 
electrophoresis at acid pH and had a molecular mass of 30 800 + 330 on 
a calibrated Sephadex G-75 column. The protease had a pH optimum of 
9,4 and 9,6 using azocasein and l14cl-haemoglobin as substrates, res-
pectively. A further 11 cytosolic 11 protease (Reinauer and Dahlmann, 
1979) was purified from the supernatant of the 33% saturation step. 
This cytosolic protease had a molecular mass of 25 000 on a calibrated 
Sephadex G-75 column. The cytosolic protease had properties similar 
to those of the chymotrypsin-like protease from mast cells, whilst the 
12 
properties of the myofibrillar protease was more trypsin-like. The 
cytosolic protease was only soluble in buffers containing 1 M KCl and 
had a pH optimum similar to that of the myofibrillar protease, in attack-
~ 
ing azocasein and haemoglobin. The myofibrillar protease was 93% 
inhibited by equimolar soybean trypsin inhibitor and only 5% inhibited 
by 0,1 µg/ml chymostatin. Leupeptin at 10 µg/ml caused a 27% inhibition. 
Clearly this protease is different from the alkaline protease described 
by Koszalka and Miller (1960a,b), because the latter enzyme is only pre-
cipitated at 40-50% ammonium sulphate saturation in crude muscle homo-
genates, whilst the enzyme of Dahlmann and Reinauer (1978) was precipi-
tated at 33% saturation. The Dahlmann and Reinauer (1978) enzyme also 
differed from the insulin-specific protease described _by Duckworth et 
al (1972), which was obtained from a 100 000 g supernatant of muscle 
homogenate. The protease of Dahlmann and Reinauer (1978) had a 
molecular mass of 31 000 compared with 25 000 for a chymotrypsin-like 
protease (Noguchi and Kandatsu, 1976) which again was similar to that 
described by Park et al (1973). The Dahlmann and Reinauer (1978) 
protease, .however, was not of the ''serine-type'' but it appeared to have 
a thiol group at the catalytic site. Furthermore, the Dahlmann and 
Reinauer (1978) ' protease was also not inhibited by prior exposure to 
60% laevadosin, whilst that of Mayer et al (1974) was completely inhibited. 
Kuo and Bhan (1980) have purified a myosin-cleaving protease from cardiac 
myofibrils of dystrophic hamsters. Steadily increasing levels of the 
enzyme correlated with the development of the cardiomyopathy. Bhan et 
al (1978) also showed, using genetically dystrophic hamsters, that a 
reduction or complete loss of the 18 000 dalton light chain (L2) occurred 
during the purification of cardiac myosin and that this was due to 
elevated levels of a protease co-purifying with myosin. This enzyme 
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was similar to that purified from rats by Murakami and Uchida (1978): 
both had a molecular mass of 26 000 daltons, a pH optimum at 9 with 
casein as substrate, insensitivity towards metal-chelating agents and 
sulphydryl-binding reagents, association with myofibrils, and the ability 
to degrade both light (L2) and heavy chains of myosin. There were, 
however, differences, such as sensitivity to l M KCl, relative degrada-
tive activities toward the light and heavy chains of myosin and the 
+2 +2 effects of 5 mM Ca or Mg Although a role of the enzyme in cardio-
myopathy has not been established definitively, there are strong reasons 
to believe that it may be an important one. The initial tissue damage 
may primarily be due to the myosin-cleaving protease, whereas the act-ion 
of the lysosomes may be involved in the later tissue destruction. 
Mayer et al (1976) have studied changes in the proteolytic activities in 
skeletal muscle of dystrophic mice, in tumour-bearing rats and in gluco-
corticoid-treated rats. These three conditions are associated with 
muscle protein loss. In mice with inherited muscular dystrophy, the 
progressive weakness and loss of active muscle mass is due to an in-
creased rate of protein catabolism rather than to a defect in protein 
synthesis (Simon et al, 1962). Similarly, enhanced catabolism of 
muscle proteins is known to occur in tumour-bearing animals and the 
ability of the growing tumour to mobilise host protein is a prominent 
feature of malignancy (Begg, 1958; Henderson and Le Page, 1959). In 
experimentally induced glucocorticoid atrophy, enhanced degradation of 
muscle proteins is associated with increased protease activity (Mayer 
et al, 1974a). Earlier reports (Thomson, 1964; Beckman, 1972) that 
a mixture of nucleotides and nucleosides (laevadosin) produced improve-
ments in patients with muscular dystrophy and the observation of Mayer 
et al (1976) that laevadosin inhibits myofibrillar protease activity 
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both in vitro and j_!!_ vivo, have been encouraging and provide an approach 
towards getting a better understanding of muscle wasting diseases. 
Park et al (1973) studied the alkaline protease purified by Holmes et 
al (1971). Holmes et al reported on an enzyme present in the homogenate 
sediment following centrifugation at 100 000 g for 30 minutes. This 
protease had a pH optimum of 11, while soybean trypsin inhibitor 
(1 µg/0,3 ml) caused a 77% inhibition of activity. The supernatant did 
not cause any inhibition and the enzyme was thus different in this 
respect from the protease of Noguchi and Kandatsu (1969, 1970). This 
protease resembled in many respects the chymotrypsin-like protease found 
i.n peritoneal mast cells (Lagunoff and Benditt, 1963) and recently puri-
fied (Kawiak et al, 1971). Skeletal muscle contains small numbers of 
mast cells situated in the connective tissue (Selye, 1965). Park et al 
(1973) used an increasing daily dose of compound 48/80, a polymer of N-
methylhomoanisylamine and formaldehyde, which was injected into rats by 
the method of Pastan and Almqvist (1966), to investigate whether the 
protease was situated in the mast cells. Treatment with 48/80 caused 
loss of most of the alkaline protease activity of the homogenates, and 
. . 
the activity was therefore considered to originate from the mast cells. 
The drug added j_!!_ vitro did ·not inhibit the protease activities nor did 
the muscle homogenate from the drug-treated rats inhibit the autolytic 
activity of the homogenate from the untreated rats. Goldspink et al 
(1971a) observed increased alkaline protease activity in denervated 
skeletal muscle of rats, expressed per mg of non-collagen protein, but 
the activity per whole muscle was not significantly changed . It is 
thus possible that this may be due to a preferential maintenance of the 
original total number of mast cells in the atrophied muscle. Increasing 
autolytic activity has been found in muscle preparations from vitamin E-
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deficient rats and hamsters (Koszalka et al, 1961), mice with hereditary 
muscular dystrophy (Berlinguet and Srivistava, 1966), rats after dener-
vation (Kohn, 1965) and rats fed on a protein-free diet (Millward, 1971). 
The contribution of mast cell proteolytic activity may be important in 
relation to these changes. A higher concentration of mast cells is seen 
in muscle of genetically dystrophic mice (Bois, 1964). 
Griffin and Wildenthal (1978) found an alkaline protease in rat cardiac 
muscle using the method of Noguchi et al (1974) and by Mayer (1976). 
The cardiac protease appeared to be similar to the skeletal protease. 
Cardiac MAP activity was found to increase with age. It increased 
even more during the development of myocardial atrophy induced by starva-
tion or diabetes mellitus, and was decreased during the development of 
thyroxine-induced hypertrophy. In these responses it was similar to 
cathepsin D (Wildenthal and Mueller, 1974; Wildenthal et al, 1975; 
Wildenthal et al, 1977), which is known to be entirely different from 
MAP in cellular distribution, class (carboxyl versus trypsin-like) and 
pH optimum. Griffin and Wildenthal (1978) have further claimed that the 
failure of the MAP activity to become elevated in tissue that was under-
going a marked increase in the number and type of non-myocytic cells, 
provided further evidence that the enzyme(s) in question was of specific 
myocytic origin. 
Murakami and Uchida (1977, 1978) have purified an endogenous protease 
which is capable of degrading myosin, from the myofibrillar fraction of 
rat hearts. The purified enzyme was unstable at neutral and alkaline 
+2 +2 pH, in the absence of Ca . Ca appeared to protect the enzyme from 
autolysis. These authors found an inhibitor in the supernatant fraction 
of heart muscle homogenates. The enzyme itself was chymotrypsin-like 
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and had a molecular mass of about 26 000. Murakami and Uchida (1979) 
showed that the protease digested myosin, M-protein, L-protein and 
troponin, but not actin, tropomyosin or a-actinin. They therefore 
conclude that the protease is directly responsible for the initial 
degradation of myosin during myofibrillar turnover in vitro. It has 
been reported that myofibrillar proteins, such as myosin, actin, 
troponin and tropomyosin, have different rates of turnover and do not 
degrade as a unit (Koizumi, 1974). The difference in susceptibilities 
of myofibrillar proteins to this protease might help to explain the 
heterogeneity in turnover rates of these proteins. Murakami and Uchida 
(1980) showed that the protease was active in the presence of EDTA and 
d .d t . C +2 f t· ·t 1 no require a or ac 1v1 y. They showed that the protease des-
troys three structures: Z-lines, M-lines and C-protein, which help to 
form bridges between neighbouring thick filaments. 
Noguchi and Kandatsu (1971) purified an ~lkaline protease with a pH 
optimum of 10. They proposed that this protease was responsible for 
the activity of autolytic breakdown of muscle proteins in the alkaline 
pH range. The enzyme was purified from the 5 000 g precipitate of rat 
skeletal muscl~ homogenates and was thus presumed to be different from 
that reported by Koszalka et al (1960), which was prepared from the 
10 000 g supernatant of homogenates. Koszalka's · protease showed a 
sharp pH optimum whilst that of Noguchi and Kandatsu had a broad pH 
optimum. 
Katunuma et al (1975) purified his enzyme from pellets obtained by 
centrifugation at 27 000 g for 20 min, of homogenates of skel~tal muscle 
of rats. An acetone powder was then prepared and further purified. 
Katunuma's pure group-specific protease had relatively high concentrations 
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of lysine and arginine, indicating that the enzyme is a basic protein. 
The molecular weights of the four proteases from skeletal muscle, liver 
and the muscle and mucosal layers of the small intestine were 17 000, 
13 000, 24 000 and 21 000 respectively. From the amino acid analyses 
and the apparent molecular mass of 24 000 determined in the case of 
the muscle-layer protease of small intestine by SOS-gel electrophoresis, 
it could be concluded that the enzyme consisted of a single polypeptide 
chain. The primary structure showed 37% and 38% identity with bovine 
chymotrypsin A and dogfish trypsin, respectively, according to incomplete 
(~ 80%) sequencing data. Katunuma's group-specific protease hydrolysed 
chymotrypsin substrates (e.g. Ac-Tyr-OEt, Ac-Phe-OEt and Ac-Trp-OEt), 
whereas trypsin-kallikrein substrates (Tos-Arg-OMe, Bz-Arg-OEt) were not 
hydrolysed. The muscle layer protease of the small intestine cleaved 
an elastase substrate (Ac-Ala-Ala-Ala-OMe) to a significant degree, 
although the rate was considerably lower than that of Ac-Tyr-OEt. A 
protease from human bone marrow cells differed from the rat proteases 
in that neither trypsin nor chymotrypsin substrates were hydrolysed, 
whilst the enzyme cleaved ester substrates of elastase but not amide 
substrates. 
The enzyme activities of these rat proteases were inhibited by chymostatin 
and a synthetic inhibitor of chymotrypsin. Leupeptin (an inhibitor of 
trypsin, papain and cathepsin B), antipain (an inhibitor of papain, 
trypsin and cathepsins A and B) and pepstatin (an inhibitor of pepsin 
and cathepsin D) were without effect on the protease activities. Elastinal 
(a specific inhibitor of elastase) inhibited the protease from human bone 
marrow cells. Both these rat and human proteases showed specificity for 
the pyridoxal-group of enzymes. Both diisopropylphosphorofluoridate 
and phenylmethane sulphonyl fluoride were effective inhibitors of the rat 
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and human proteases which indicated that these were typical serine 
proteases. Chemical modifications of the enzymes showed that serine, 
histidine and perhaps tyrosine were essential for activity. Usually, 
in the case of serine proteases, the serine hydroxyl and histidine 
labile protons play essential roles in the splitting of the peptide 
bond. 
The four rat and human proteases are thus apparently clearly distin-
gu·is·hable from each other. The rat enzymes are chymotrypsin-like, 
while the human protease is el.astase-like. The protease from the 
muscle layer of the small intestine of the rat cleaves one of the 
elastase substrates whereas the others do not. The liver and skele-
tal muscle enzymes differ in that the molecular mass of the liver 
protease is lower (13 000 compared to 17 000) and the liver protease is 
eluted from a CM-cellulose column by 0,02 M phosphate buffer. These 
group-specific proteases differ from lysosomal proteases in th~ following 
points: 
(1) Optimum pH is in the alkaline range whereas cathepsins act best in 
acidic solutions, 
(2) the proteases are serine proteases whereas most of the lysosomal 
proteases are thiol or carboxyl enzymes, and 
(3) the proteases have chymotrypsin-like properties. 
Chymotrypsin-like proteases have also been found in human seminal plasma 
(Syner and Moghissi, 1972), the isolated granules of mast cells from the 
peritoneal cavity of the rat (Kawiak et al, 1971; Vensel et al, 1971) 
and human neutrophil granulocytes (Rinder- Ludwig and Braunsteiner, 1975). 
All these proteases are active on tyrosine esters. The plasma from 
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human seminal fluid is, however, unaffected by diisopropylphospho-
fluoridate. Tos-Phe-CH2Cl inhibiteci the latter two enzymes. The 
protease from the muscle layer of the small intestine is unaffected by 
Tos-Phe-CH2Cl but it is difficult, as yet, to distinguish this enzyme 
from the mast cell and granulocyte proteases. 
Skeletal muscle contains neutral proteases, in addition to cathepsins, 
making discrimination between these and the chymotrypsin-like protease 
.important. The molecular mass of the protease reported by Huston and 
Krebs (1968) is 110 000, which is much larger than that of any group-
specific protease. The protease of Mayer et al (1974) was unaffected 
by Ca+2, that of Okitani et al (1974) was activated by Ca+2, whilst the -
group-specific skeletal muscle protease was inhibited by Ca+2 Neutral 
proteases have also been reported in liver mitochondria (Fitzpatrick 
and Pennington, 1969; Gear et al, 1974) and rat liver peroxisomal 
fraction (Gray et al, 1970), but these enzymes have not been purified and 
characterised. 
The amounts of Katunuma's serine protease in various types of muscles 
differ greatly; ac~ivity being higher in red muscle than in white, 
whereas none could be detected in cardiac muscle. High activity was 
observed in immature erythroblasts and granulocytes among bone marrow 
cell components, but low activity was observed in mature erythrocytes, 
granulocytes and lymphocytes. The rat liver group-specific protease 
is associated with the mitochondrial inner membrane. Regenerated and 
neo-natal liver show very low protease activities (Banno et al, 1975). 
Activity reached a minimum (< 30%) about 72 hours after hepatectomy 
relative to sham-operated or normal animals. 
Possible mechanisms for the regulation of protease activities under 
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different physiological conditions include: 
(1) de novo synthesis of the protease, 
(2) translocation within the cell, and 
(3) activation/inhibition of the proteases. 
Katunuma has isolated a peptide inhibitor in the same sub-cellular · 
fraction as the protease. 
Thus it can be seen that there have been reports of a number of chymo-
trypsin-like proteases, especially during the last decade, which can be 
detected in muscle homogenates incubated at alkaline pH. These are · sum-
marised in Table 1.1 (Bird et al, 1980). Due to their optimum activity at 
alkaline pH, the proteases have generally been referred to as "alkaline 
proteases". Most of these enzymes have been reported to be inhibited by 
diisopropyl phosphorofluoridate (Dip-F) or phenylmethansulfonylfluoride 
(Pms-F) and therefore they are classified as "serine proteases". However, 
clarity as to the precise nature of these enzymes has not yet been achieved. 
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Table 1 .1. Muscle serine proteases "alkaline proteases". 
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1 .4 . OBJECTIVES OF STUDY 
Protein turnover is an important factor in the metabolism of cells and 
can broadly be divided into two phases. The first phase involves the 
synthesis of the proteins and has been subjected to intense scrutiny in 
the past. The second phase involves the degradation of these proteins 
and has not to date been nearly as well characterised. However, the 
importance of protein catabolism is now being realised and the process 
has begun to be studied in more detail. These studies have· shown the 
presence of new groups of proteases - one of these being those proteases 
with optimal activity in the alkaline pH range. These proteases appear 
to form a new group _which is potentially capable of playing an important 
role in the catabolism of proteins. 
As already reviewed, some of these alkaline proteases have been charac-
terised to varying degrees in the past. One of the major problems has 
been the separation of the myofibrils from the alkaline protease. This 
has been achieved in the present investigation by means of a pyrophosphate-
wash which removed a factor which appears to assist in the binding of the 
protease to the myofibrillar proteins. Furthermore, I have attempted to 
show that the alkaline proteases are not a single entity but that there 
are a number of different alkaline proteases. The presence of a physio-
logical MAP inhibitor, which is capable of playing an important role in 
regulating the activity of the alkaline protease, has been verified. An 
alkaline protease similar to the principal enzyme studied was also demon-
strated and partially purified from rat cardiac muscle. 
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CHAPTER 2 
PURIFICATION OF A 11 MYOFIBRILLAR ALKALINE PROTEASE 11 FROM 
RAT SKELETAL MUSCLE 
2 .1. INTRODUCTION 
A major problem in the stud/ of the myofibrillar alkaline protease has 
been the great difficulty experienced in separating the alkaline protease 
from m.Yofibrillar components. Clearly, if this separation is achieved, 
the enzyme can be studied in greater detail, since the reaction conditions 
can be more sensitively controlled in the absence of a large excess of 
myofibrillar proteins. In order to establish that the enzyme is not 
associated with particulate fractions in skeletal muscle homogenates (and 
therefore in the intact tissue) other than m.YOfibrils, I initially 
purified 11 washed m.Yofibrils 11 by the standard technique and then proceeded 
to separate the alkaline protease from the myofibrils. This showed that 
the enzyme was not derived from mitochondria or nuclei, etc. but that it 
was a true myofibrillar alkaline protease. 
2.2. RESULTS 
2.2.l. Standardisation of MAP assays 
2.2.1.1. Methods of assay 
Four methods were tested to establish an assay which was convenient and 
sensitive for the detection of alkaline protease activity. All four 
of these methods involved the use of either denatured casein or azocasein 
as a substrate for the protease. The individual assay procedures used 
are described in Chapter 4 (4.2). The following substrates and methods 
of assay were used: 
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(a) Denatured casein as substrate; tyrosine release measured. 
(b) Denatured casein as substrate; A280 of the TCA-supernatant measured. 
(c) I 125 rl -labelled casein as substrate; release of TCA-soluble radio-
activity measured. 
(d) Azocasein as substrate; A340 of TCA-supernatant measured. 
Figs. 2.1 to 2.4 show a typical reaction profile for each of these four 
assay methods, using the same enzyme concentration, over a 60 minute 
incubation period . . The standard curve for the fluorimetric detection 
of tyrosine was linear up to 20 nmoles tyrosine (Fig. 2.5). 
The tyrosine-release method was linear for an hour and was very sensitive. 
The A280 method showed only a very small change in absorbance ove
r the 
incubation period and the procedure was abandoned becau$e of its insen-
sitivity. The measurement of l125 rl -tyrosine release from labelled 
substrate proteins was very sensitive, and the time course was linear 
over the full incubation period. However, this method was also abandoned 
because of the laborious preparation of the l125 rl-labelled substrate and 
because a rapid rise in background levels occurred during storage of the 
material, thus making this method cumbersome for rapid enzyme assays. 
The azocasein method was ultimately preferred because it was an economical, 
rapid and sensitive method of determining the alkaline protease activity. 
This method was also highly reproducible. 
A unit of MAP activity was defined as that amount of enzyme, in the 
standard assay mixture, which would cause an increase in the absorbance 
of the TCA-supernatant of 0,001 at 340 nm in 60 minutes under the stan-
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Fig. 2.1. MAP activity using denatured casein as substrate. MAP 
was prepared as described in 4.4.1 - 4.4.2, and protease 
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Fig. 2.2. MAP activity using denatured casein as substrate. MAP 
was prepared as described in 4.4.1 - 4.4.2, and protease 
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Fig . . 2.3. MAP activity using 112511-casein as substrate. MAP 
was prepared as described in 4.4.1 - 4.4.2, and proteo-
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Fig . 2.4, MAP activity using azocasein as substrate. MAP was 
prepared as described in 4.4.1 - 4.4.2, and proteolytic 
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Tyrosine standard curve. Tyrosine concentrations 
were measured fluorimetrically as described in 
4.2.1.3. 
29 
2.2.1 .2. Time dependence of MAP reaction 
The time dependence of MAP activity under standard reaction conditions 
is shown in Fig. 2.4. The alkaline protease activity was found to be 
linear over a 60 minute incubation period, in the presence of excess 
substrate. An incubation period of 45 minutes was used during the 
routine enzyme activity determinations. 
2.2.1.3. pH-dependence of MAP reaction 
The pH dependence of MAP activity under standard conditions is shown in 
Fig. 2.6. This assay was performed using a solubilised washed myo-
fibrillar precipitate which may have contained a mixture of 11myofibrillar 
alkaline proteases 11 : The enzyme was in any case routinely assayed at pH 
9,0 during the purification procedure to e~sure that only alkaline 
proteases and not acid- nor neutral proteases were measured. 
2.2.2. Isolation and purification of MAP (Description of a typical 
preparation). 
2.2.2.1. Sample preparation 
Rat hind leg muscles (237 gram) were trimmed of excess fat and connective 
tissue, cut into small pieces and then homogenised in 10 vols (ml/g) 
of cooled pyrophosphate-enriched low salt buffer pH 7,1, as described 
in the Methods (4.4.1 .). 
2.2.2.2. Washed myofibril preparations 
The homogenate prepared above (2 745 ml) was centrifuged at 800 g for 
10 minutes at 4°C. The supernatant was discarded and the precipitate 
was re-suspended in 5 vol. of the pyrophosphate-enriched low-salt 
30 
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Fig. 2.6. Effect of pH on MAP activity. MAP was prepared from . 
skeletal muscle as in 4.4.1 - 4.4.2. MAP activity 
was assayed as described in 4.2.3. 
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buffer pH 7,1. The suspension so produced was called suspension A 
(1 440 ml). These washes were repeated a further three times. On 
the fourth rinse, the buffer included Triton X-100 (1 %) in addition to 
the normal constituents. The precipitate was then washed a further 
two times with the normal pyrophosphate-enriched low-salt buffer and 
the resulting final precipitate was called the washed myofibril preci-
pitate. 
2.2.2.3. Wash at a high concentration of pyrophosphate 
The washed myofibril precipitate was stirred in 10 vols of fresh 20 mM 
tetra-sodium pyrophosphate (pH > 10) for l hour at 4°C. The resulting 
suspension was centrifuged at 8 000 g for 30 minutes at 4°C. The 
resulting supernatant was discarded, whilst the precipitate was called 
· the "pyrophosphate-wash preci pitate 11 • 
2.2.2.4. Solubilisation at high salt concentrations 
The "pyrophosphate-wash precipitate" was stirred for l hour at 4°C in 10 
vols of 0,6 M KCl. Thereafter, the mixture was centrifuged at 48 000 g 
for 30 minutes at 4°C. The supernatant was carefully decanted and 
retained: the 11 KCl-supernatant 11 (880 ml). 
2.2.2.5. Dialysis of the 11 KCl-supernatant 11 
The 11 KCl-supernatant 11 solution was dialysed overnight at 4°C against 10 
vols of a 5 mM potassium phosphate buffer containing 0,1 mM OTT (pH 8,5). 
The equilibrated dialysate was then centrifuged at 4°C for 15 minutes 
at 48 000 g. The supernatant was retained and called the 11 dialysed 
supernatant" (816 ml). 
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2.2.2.6. CM-Sephadex C-50 batch step 
The "dialysed supernatant" was stirred for 30 minutes at 4°c in the 
presence of pre-equilibrated CM-Sephadex C-50 (prepared as described 
in 4.4.6), using l gram dry CM-Sephadex C-50 per 100 mg protein. The 
suspension (0 M NaCl) was centrifuged for l minute at l 500 g at 4°C. 
The CM-Sephadex C-50 sediment was then stirred for 30 minutes at 4°C 
in 0,7 M NaCl - 10 mM Tris-HCl, pH 6,0. The suspension (0,7 M NaCl) 
was again centrifuged as before. The sediment was stirred for 30 
minutes at 4°c in a 1,5 M NaCl - 10 mM Tris-HCl, pH 6,0 solution. The 
suspension (1,5 M NaCl) was similarly centrifuged. The final super-
natant was decanted and retained: the 11 CM-l ,5 M supernatant 11 (379 ml). · 
The 11 CM-l,5 M supernatant 11 was immediately taken and dialysed overnight 
at 4°C against 10 vols of 5 mM potassium phosphate buffer and 0,1 mM 
OTT at pH 8,5. 
2.2.2.7. Ultrafiltration 
The "dialysed CM-1,5 M supernatant" was filtered at 4°C through an 
Amicon membrane filter, using a PM-10 disc at a pressure of 4,5 bar; 
compression being achieved by using nitrogen. The filtration was cqn-
tinued until an approximately 3-fold concentration had been achieved. 
2.2.2.8. CM-Sephadex C-50 column chromatography 
The concentrated CM-1 ,5 M solution (120 ml) was applied to an equili-
brated CM-Sephadex C-50 column (1,4 x 5,5 cm) and the sample was eluted 
using a linear gradient of NaCl (0 - 0,7 M) in a 10 mM Tris-HCl, pH 6,0 
buffer (See Methods 4.4.8). All fractions were assayed for MAP 
activity by the standard azocasein-linked spectrophotometric method. 
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The protein elution profile was obtained using the Bio-Rad colour 
reagent; the standard curve for protein using this reagent was performed 
using bovine serum albumin and was found to be linear up to l mg protein/ 
ml (Fig. 2.7). 
The 11 bound protein 11 was found to elute primarily at 0,48 M NaCl, while 
the 11 bound enzyme 11 was found to elute at 0,66 M NaCl (Fig. 2.8). The 
active peak tubes were pooled (28 ml) and dialysed overnight at 4°C 
against 10 vols 5 mM potassium phosphate buffer a-nd 0,1 mM OTT (pH 8,5). 
The dialysate was then conGentrated by vacuum dialysis at 4°C to a 
final volume of 3 ml. 
2.2.2.9. Sephadex G-75 chromatography 
The concentrated material was now applied to a 1 ,6 x 90 cm Sephadex 
G-75 column at 4°c. The sample was eluted using a 0,6 M KCl - 10 mM 
Tris-HCl, pH 7 ,0 solution (4.4.9). The fractions collected we.re assayed 
for protein content, and enzyme activity (Fig. 2.9): the MAP activity 
eluted as a peak distinct from the protein peak. 
The specific activity of MAP was found to increase from 59,4 units/mg 
in the homogenate to a final specific activity of 602 676 units/mg in 
the pooled Sephadex-G-75 enzyme peak. 
of 10 215-fold (Table 2.1). 
This represents a purification 
2.2.3. Determination of the molecular mass of MAP 
A molecular weight calibration curve for the Sephadex G-75 column is 
shown in Fig. 2.10. The molecular weight of the partially purified 
MAP, as determined by gel filtration of the concentrated enzyme, was 
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Fig. 2.10. Molecular weight calibration curve for Sephadex G-75 column 
·-
(1 ~6 x 90 cm), equilibrated in 10 mM Tris - 0,6 M KCl-HCl, 
pH 7,0. The standards and their molecular weights were: 
NAO+ (664); cytochrome C (12 500); a-chymotrypsin (25 000) 
and bovine serum albumin (68 000). 
11 P11 indicates the fraction in which MAP eluted. 
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2.3. DISCUSSION 
The present study describes the purification of an alkaline protease 
from rat skeletal muscle. A 10 215-fold purification of the alkaline 
protease was obtained at a nett yield of 5% of the total original 
alkaline protease activity. However, the actual yield of this 
specific alkaline protease was actually higher as the .original homo-
genate contained a mixture of alkaline proteases. The alkaline protease 
which was isolated could not be separated from the fT\YOfibrils by 1% 
Triton X-100, stirring or differential centrifugation. The protease was 
found to be solubilised only in solutions containing a salt concentration 
of at least 0,6 M KCl, up to the washed myofibrillar precipitate stage. 
Indeed, upon repeated solubilisation by 0,6 M KCl and sequential dialysis 
of the washed myofibrillar precipitate, the protease was on all occasions 
found to be present in the same fraction as the myofibrils. As the 
alakline protease could be separated from the myofibrils and was then 
soluble in a buffer free of KCl, it can be concluded that the protease 
was attached either to organelles which sedimented with the myofibrils 
or that it had become absorbed onto the fT\YOfibrils. The latter would 
appear to be the true explanation since the organelles were separated 
from fT\YOfibrils by differential centrifugation and by Triton X-100 
-
treatment, and in addition the only particles visible in the washed 
myofibril precipitate when examined by light microscopy were myofibrils. 
I have therefore called this purified enzyme a fT\YOfibril-associated 
alakline protease, and it fulfils the requirements of a 11myofibrillar 
alkaline protease" as described by Pennington et al (1973). 
The protease was active at 37°c and was capable of utilising both 
denatured casein and azocasein as substrates. Enzyme activity was 
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measured by the rate of increase of TCA-soluble material as measured 
spectrophotometrically at 340 nm. This method was found to be the 
most rapid and reproducible as well as the most convenient of the 
enzyme assay procedures tested. The protease activity was found to 
be linear for the first 60 min in the presence of an excess of substrate, 
but only the first 45 min were utilised during the routine enzyme assay. 
The proteases in the washed myofibrillar precipitate were active over 
the pH range of 6,9 to 12,0. The highest protease activity was 
expressed at a pH of 9.0. The protease activity at pH 6,9 and 12,0 
were 41 % and 23%, respectively, of that observed at pH 9,0. At pH 7,4, 
the proteolytic activity was 54% of the optimal proteolytic activity. 
However, the washed myofibrils contained more than one alkaline protease 
(cf. 3.2.l) with activity at pH 9,0, but by measuring the enzyme activity 
and consistently checking it'.schymostatin sensitivity (cf. 3.2.4.4),' 
the protease of molecular mass 31 600 could be separated from the rest. 
An increased sensitivity to chymostatin was observed with increasing 
purification of the alkaline protease (cf. 3.2.1.3). 
The alkaline protease was separated from the ll\YOfibrils by means of a 
prior exposure to an alkaline solution of 20 mM sodium pyrophosphate, 
followed by solubilisation of the myofibrils. Upon subsequent dialysis 
the protease activity remained in the supernatant fraction whilst the 
myofibrils were precipitated. This method is less severe than that of 
Dahlmann and Reinauer (1978) who used bovine trypsin coupled to Sepha-
rose 48 to "lower the viscosity" of the solution. Their solubilisation 
step showed a 3-fold increase in total proteolytic activity which was 
shown to be due to leakage of free trypsin from the Sepharose conjugate. 
Their treatment of the homogenate solubilised in 1 M KCl for the prepara-
tion of 1.'myofibrils 11 was also less specific as they classified everything 
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which precipitated at 33% saturation with respect to anmonium sulphate 
as myofibrillar proteins. 
The alkaline protease purified in this work was unstable at a pH lower 
than 7,0 . A decrease in protease activity of about 33% was observed 
if the enzyme solution was left in a buffer at pH 6,0 overnight, whilst 
at pH 8,5 there was less than a 1% decrease in protease activity over a 
one-week period in the presence of excess subtrate. Thus the enzyme 
was assayed immediately following the steps involving buffers at pH 6,0 
(CM-Sephadex C-50 batch and column steps) and thereafter the enzyme was 
immediately dialysed against a 10-fold excess of buffer at pH 8,5. 
The 11\YOfibrillar alkaline protease which has been purified here is 
clearly different from the insulin-specific protease described by 
Duckworth et al (1972) as their protease was obtained from a 100 000 g 
supernatant of muscle homogenate. Similarly, the protease is different 
from that of Koszalka et al (1960) which was purified from the 10 000 g 
supernatant of rat skeletal muscle. 
The apparent molecular mass of 31 600 determined by gel filtration on 
Sephadex G~75 compares favourably with the value of 30 800 obtained by 
Dahlmann and Reinauer (1978) using gel filtration. Beynon and Kay 
(1978) purified a neutral protease from intestinal muscle of rats which 
had a molecular mass of 33 000. Murakami and Uchida (1978) purified 
an alkaline protease from rat heart and Kuo and Bhan (1980) from hamster 
heart, both proteases having a molecular mass of 26 000. Bhan et al 
(1978) purified a myofibril-associated alkaline protease which had a 
molecular mass of about 14 000 by gel filtration. The molecular mass 
obtained for the purified protease appears to be different from that / 
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obtained in the case of a chymotrypsin-like protease (Noguchi and 
Kandatsu, 1976) of 25 000 daltons, which was similar to that described 
by Park et al (1973) and Holmes et al (1971). The purified protease 
~ 
clearly differs from the group-specific protease from rat skeletal 
muscle purified by Katunuma et al (1975) which had a molecular mass of 
13 000. The purified protease also differs from the alkaline ca2+-
dependent protease purified by Huston and Krebs (1968), which had a 
molecular mass by gel filtration of 110 000, as well as from the 
protease purified from liver (Burgher et al, 1972) which had a molecular 
mass of 80 000 by gel filtration. The serine protease purified by 
Sanada et al (1978) was found to have a molecular mass of approximately 
23 000 by sedimentation equilibrium studies. Woodbury et al (1978) 
found that both the mast cell protease and a skeletal muscle protease 
had a molecular mass of 29 000 by PAGE in the presence of SOS and OTT 
and that this apparent molecular mass decreased in both cases to 26 000 
in the presence of 8 M urea. 
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CHAPTER 3 
CHARACTERISATION OF MAP ENZYME SYSTEM 
3.1. INTRODUCTION 
The confusion still existing concerning the identity of MAP enzyme(s) 
in muscle is largely due to the heterogeneity of the systems that have 
been studied and assays conducted on impure preparations. Substrates 
and enzyme preparations have also differed markedly in the systems used 
by different researchers. 
One area where marked differences have been reported is that of the 
molecular mass of the MAP. Values ranging between 13 000 (Katunuma 
et al, 1975) and 110 000 (Huston and Krebs, 1968) have been repo_rted. 
Other criteria used to define MAP enzymes have been their apparent 
subcellular location, their sensitivity to a variety of protease 
inhibitors and metal ions, as well as the absence or presence of detec-
table enzyme activity in various organs . 
Although there were areas of similarity between the proteases studied 
by some researchers, there were such striking differences between the 
proteases studied in some cases that these differences could not be 
attributed only to experimental nor procedural differences. Clearly, 
thus, there is an indication that the alkaline proteases are not a 
single entity, but probably a group of similar enzymes. 
It is for this reason that I ha~e investigated, after application of 
the purification procedures described in the previous chapter, the 
properties of the purified enzyme to see whether there is in fact a 
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single MAP enzyme and to compare the MAP which I have studied to those 
investigated by other workers. Whilst a demonstrably pure enzyme 
preparation would be ideal for a thorough study, the properties of my 
particular enzyme preparation have been explored to assist in the 
positive identification of the enzyme concerned. Furthermore, a 
comparison with many of the other "MAP enzymes" studied can be made. 
3.2. RESULTS 
3.2.1. Evidence of a second alkaline protease 
3.2.1.1. Sephadex G-75 chromatography 
3 ml of the dialysed supernatant (See 2.2.2.5) was placed on a 1 ,6 x 90 cm 
Sephadex G-75 column and eluted by the standard method with 0,6 M KCl -
10 mM Tris-HCl, pH 7,0 (4.4.9). The resulting enzyme elution profile 
showed two distinct enzyme peaks of unequal magnitude (Fig. 3. 1). 
3.2.1.2. CM-Sephadex C-50 chromatography 
A sample (10 ml) of dialysed supernatant (See 2.2.2.5) was placed on a 
1 ,4 x 2,5 cm CM-Sephadex C-50 column and eluted step-wise with 15 ml 
0,2 M NaCl - 10 mM Tris-HCl, pH 6,0 followed by 15 ml 0,7 M NaCl -
10 mM Tris-HCl, pH 6,0. Fractions of 3,3 ml were collected. These 
were assayed for protein content and enzyme activity by the standard 
procedures (4.4.8). The enzyme activity eluted in two separate peaks 
of unequal magnitude (Fig. 3.2). 
3.2.1 .3. Gelatin gel electrophoresis 
A dialysed supernatant fraction (See 2.2.2.5) was applied to a 0,1 % 
gelatin - 11 % polyacrylamide slab gel according to the procedure 
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Fig. 3,2. CM-Sephadex C-50 chromatography of MAP from rat skeletal muscle. 
MAP was prepared as described in 4.4.1 to 4.4.5. A sample 
of 10 ml (19,7 mg protein) was applied to the column and 
elution was with a sequential step-wise gradient of NaCl from 
0,2 M to 0,7 M NaCl (l5 'ml of each was used). The flow rate 
was 10 ml/hr and each fraction contained 3,125 ml. Aliquots 
were assayed for proteolytic activity as described in 4.2.3 
and for protein concentration as described in 4.3. 
47' 
described in Chapter 4 (4.5.2). In the absence of chymostatin in the 
incubation buffer, two clear lysis bands were observed. These corres-
ponded to molecular weights of 46 800 and 32 900 when compared with 
standard myofibrillar proteins (Fig. 3.3). The presence of 10 µg/ml 
chymostatin in the incubation medium was associated with only one 
lysis band, normally that of th_e protease of higher molecular weight. 
An identical gel stained with coomassie blue showed a protein Dand 
corresponding to 32 500 at the site comparable to the chymostatin-
sensitive protease, relative to standard myofibrillar protein markers. 
This clearly shows that the two bands do not represent artefacts due 
to enzyme aggregation or polymerisation, since the two enzymes are 
affected differently by the inhibitor, chymostatin. 
3.2.2. Presence of a MAP inhibitor 
Skeletal muscle was obtained by the normal procedure and a homogenate 
was prepared. The homogenate was centrifuged at 8000 g for 10 minutes 
at 4°C. The precipitate was then resuspended in pyrophosphate-
enriched low-salt buffer (Fig. 3.4). The three enzyme-containing 
solutions were then all assayed for enzyme activity and protein con-
centration (Table 3.1). 
The enzyme activity in the suspension showed a nearly 2-fold increase 
over that originally assayed in the homogenate. The addition of 
supernatant to the suspension caused a nett decrease in the expected 
combined enzyme activity (Table 3.1). 
A similar sudden increase in activity was also found as shown in Fig. 3.5, 
following centrifugation of the "supernatant 811 fraction for 60 min. at · 
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mm migrated 
Fig. 3.3. Molecular weight calibration curve for gelatin-PAGE gel. The 
standards and their molecular weights were: lysozyme (14 000); 
soybean trypsin inhibitor (21 000); carbonic anhydrase (30 000); 
actin (44 000); albumin (68 000); phosphorylase (94 000) 
and myosin heavy chain (200 000). 11 011 indicates the distance 
migrated by the chymostatin-insensitive protease and 11 P11 that 
of the chymostatin-sensitive protease. 
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Rat skeletal muscle 
Homogenised in 









Fig. 3.4. Purification schedule to demonstrate presence of inhibitor. 
































































































































enzyme activity was recorded after the ultracentrifugation. 
3.2.3. Subcellular distribution of MAP activity 
The rat skeletal muscle homogenate was prepared by the standard procedure 
as given in Methods (4.4.1. - 4.4.2.). The enzyme sample was then 
treated as shown in the flow chart of Fig. 3.5. All the fractions were 
assayed for enzyme activity and protein concentration (Table 3.2). 
The results show that the MAP activity was predominantly present in the. 
fraction which precipitates with the myofibrils; only a small propor-
tion of the enzyme activity was associated with the mitochondrial-
lysosomal pellet. The MAP activity present in the mitochondrial-
lysosomal pellet may have been due to contamination as small quantities 
of myofibri.ls were detected (using PAGE) in the mitochondrial-lysosomal 
fraction ( 4. 5. l . ) . · 
3.2.4. Properties of MAP 
3.2.4.l. Effect of temperature on enzyme stability 
Samples of the dialysed supernatant (See 2.2.2.5.) were incubated for 
60 minutes at 4°C, 37°c and 6o0 c respectively. Protease activity in 
the samples was then determined by the standard assay method and com-
pared with a sample which had been assayed immediately after preparation 
(Table 3.3.). 
At 37°c and below, no significant decrease in enzyme activity was 
observed for a period of 1 hour, while at 6o0 c the enzyme activity was 
almost totally destroyed. Presumably, the enzyme activity at 37°C 



































































































































































































































































































































































































































































EFFECT OF TEMPERATURE ON ENZYME STABILITY 










* Enz. samples were incubated at the given temperature for 
60 minutes before being assayed for protease activity. 
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of myofibrillar proteins and in a pure enzyme preparation a decrease in 
enzyme activity would be expected. 
3.2.4.2. Effect of salt concentration on enzyme solubility 
1,0 gram fractions of washed myofibril precipitates were treated at a 
range of KCl concentrations as shown in Fig. 3.6. The initially un-
dissolved myofibrils were solubilised by 0,6 M KCl. The various 
solutions were assayed for enzyme activity and protein concentrations 
(Table 3.4.). The solubility of the enzyme increased as the salt 
concentration was raised, which paralleled the solubilization of the 
myofibrils. 
3.2.4.3. Effect of pyrophosphate concentration on enzyme solubility 
1,0 gram fractions of washed myofibril precipitate were treated a't ·a 
range of fresh pyrophosphate concentrations, as shown in Fig. 3.7. The 
different enzyme solutions were assayed for enzyme activity and protein 
concentrations (Table 3.5.). These results show that at 10 mM pyro-
phosphate, both the enzyme and associated proteins become solubilised, 
while at 20 mM pyrophosphate, very little enzyme activity .was solubi-
lised despite a large amount of protein going into solution. 
3.2.4.4. Effect of proteolytic enzyme inhibitors on MAP 
Samples of dialysed supernatant (See 2.2.2.5.) were used to assess the 
effect of various proteolytic enzyme inhibitors on the activity of MAP. 
The inhibitors tested were chymostatin, soybean trypsin inhibitor, 
pepstatin, leupeptin and EGTA. The effects of these inhibitors on 
enzyme activity, expressed in comparisoh with the activity given by a 
control sample, are shown in Table 3.6. 
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l ,0 gram washed myofibrils 
Centrifugation 
Precipitate 
Stir at 4°C for 
2 hours with 
10 vols (v/m) 
of O ,6 M KCl 
Solubilised precipitate 
Stir at 4°C for 
2 hours, with 
separate solutions 
JlO vols (v/ml)J 
of KCl * 
Supernatant 
* 0 M; 0,2 M; 0,4 M and 0,6 M KCl solutions were used. 









































































































































































































































1,0 gram washed myofibrils 
Centrifugation 
Precipitate 
Stir at 4°C for 
2 hours with 
0 ,6 M KCl 
I l O vo 1 s ( v / m) I 
Solubilised precipitate 
Stir at 4°C for 
2 hours with 
separate solutions 




* 0 mM, 10 mM and 20 mM Na4P2o7 solutions were used. 






















































































































































































































EFFECTS OF INHIBITORS ON MAP ACTIVITY 
Inhi biter Inhibitor concentration (µg/ml)* Protease activity 
None 100 
Pepstatin 5 104 
Leupeptin 10 99 
Soybean Trypsin 10 67 
Inhibitor 
Chymostatin 6,6 5 
DMSO 100 
EGTA 2 90 
* All enzyme inhibitors were used in µg/ml concentrations, except 
EGTA which was used in millimolar concentration. 
(%) 
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MAP activity was unaffected at the concentrations used of pepstatin 
(5 µg/ml), leupeptin (10 µg/ml) and to a lesser degree EGTA (2 mM). 
10 µg/ml soybean trypsin inhibitor decreased enzyme activity by 33%. 
MAP activity was especially sensitive to chymostatin - 95% inhibition 
occurred at 6,6 µg/ml chymostatin. This may have been partly due to 
chymostatin being dissolved in DMSO, but no inhibition was observed 
in the presence of pure DMSO at the same concentration. 
The chymostatin-sensitivity of the major MAP (MW 32 900), as compared 
with the chymostatin-i nsensiti vi ty of the mi nor MAP (MW 46 800) 
(shown in 3.2.1.3.), was utilised in a preliminary study of the exis-
tence of the major alkaline protease in compound 48/80 treated (mast 
cell granule depleted) rats. The rats were treated as described in 
the Methods (4.4.10). Histology of skeletal muscles confirmed that 
compound 48/80 caused degranulation of the mast cells (Fig. 3.8). 
The dialysed supernatant prepared from such successfully granule-
depleted rats contained significant levels of alkaline protease activity 
of which up to 63% was inhibited by 6,6 µg/ml chymostatin. 
3.2.~. Presence of MAP in rat heart tissue 
Heart muscle was removed from male fed rats and freed of excess fat and 
blood vessels. The heart was then cut into small pieces and homogenised 
as in the case of rat skeletal muscle (4.4.l.). The "heart MAP 11 was 
then further purified according to the procedure for 11 skeletal MAP 11 
purification up to the formation of the dialysed supernatant (cf. 2.2.2.5). 
The various enzyme fractions were assayed for enzyme activity by the 
standard azocasein - A340 method (Table 3.7). 





Fig. 3.8. (a) Normal rat skeletal muscle (Giemsa stain) showing 
the presence of mast cells with granules. 
(b) Compound 48/80-treated rat skeletal muscle (Giemsa stain) 
showing a decrease in the number of mast cell granules. 
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TABLE 3.7. 
PURIFICATION OF MAP FROM RAT CARDIAC MUSCLE 
Sample Vol. (ml) Enzyme activity Total Activity (U) 
Units/ml 
Homogenate 21 414 8 694 
Suspension . 24 354 8 496 
Supernatant 18 96 l 728 
KCl supernatant 16 245 3 920 
Dialysis supn. 15 85 l 275 
64 
very similarly to that detected in skeletal muscle. The heart form 
also behaves as a 11 myofibrillar-protease 11 up to the dialysis step. 
3.3. DISCUSSION 
The results described in this and the previous chapter point to the 
existence of two 11 myofibrillar alkaline proteases 11 in washed myofibrillar 
precipitates. Evidence of a second protease was found using three 
different separation methods as well as by means of inhibitor studies. 
The molecular masses of the two proteases were found to be 82 900 and 
46 800 daltons . Inhibitor studies basee on the premise that the same 
entity would not change its sensitivi.ty upon polymerization showed that 
the two entities were indeed different: Thus only the alkaline protease 
of molecular mass 32 900 was sensitive to chymostatin. This molecular 
mass determined by gel electrophoresis corresponded favourably with the 
molecular mass of 31 600 found by gel filtration, to give an average 
estimate of 32 250 + 650. 
Evidence for the presence of a MAP inhibitor in the homogenate super-
natant was shown by the 184% yield of proteolytic activity which followed 
on the removal of the supernatant. Upon ultracentrifugation of the 
supernatant at 100 000 g for 60 min, the 11 inhibitor 11 remained in the 
supernatant whilst a relative 11 yield 11 of 290% of the proteolytic activity 
was recorded in the precipitate. Earlier it was argued that the rate 
of protein degradation may be affected by either a change in structure 
of the protein being degraded and/or by an alteration in the activity 
of the enzyme system degrading the enzyme (cf. l .l . and 1.3.). Thus 
the presence of a "physiological inhibitor" may play a significant role 
i!:!_ vivo in controlling the activity of a 11myofibrillar alkaline protease". 
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Katunuma et al (1976) have also reported the presence of a physiological 
inhibitor. They also showed a marked increase in total proteolytic 
activity during some steps in the purification of the protease. They 
purified a specific inhibitor, from skeletal muscle, which had a 
molecular mass of less than 5 000. A kinetic study of the inhibitor 
showed a typical non-competitive type of inhibition. The effects of 
the inhibitor on several other common proteases were also studied. 
Proteases such as pronase, trypsin and chymotrypsin were not inhibited. 
As the protease isolated by Katunuma et al (1976) is clearly different .. 
from the protease isolated in this study, their inhibitor is probably 
not the same inhibitor as that observed by me. The presence of the 
inhibitor does, however, clearly demonstrate a possible specific 
physiological control of the activity of a myofibrillar alkaline 
protease, which may be operative in living muscle cells. 
The myofibrillar alkaline protease was present mainly in the fraction con-
taining the myofibrils obtained by differential centrifugation. Light 
microscopy and PAGE confirmed that the presence of MAP in other fractions 
was always associated with myofibrils or myofibrillar proteins. 
The protease was stable for a period of one hour at 4°C and 37°c but was 
inactivated at 60°c. The proteolytic activity decreased rapidly on 
standing at pH 6,0, whilst the enzyme was stable in the cold for more 
than a week at pH 8,5. 
The protease was solubilised by 0,6 M KCl in a similar pattern to the 
solubilisation of the myofibrils. Upon repeated solubilisation and 
dialysis of the myofibrils, the protease was always found in the 
fraction containing the myofibrillar proteins. Incubation of the 
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myofibrils with 20 mM sodium pyrnphosphate resulted in the release of 
only trace amounts of proteolytic activity. Thus, as was shown earlier, 
the protease is attached to the myofibrillar proteins and also is not 
solubilised by 20 mM sodium phyrophosphate. However, upon subsequent 
solubilisation with KCl and dialysis, the proteolytic activity remained 
in the supernatant. This implies that although the 20 mM sodium pyro-
phosphate did not solubilise the protease it did solubilise some factor 
which assisted in the attachment of the protease to the myofibrillar 
proteins. Thus upon subsequent dialysis of the solubilised pyrophos-
phate precipitate (i.e. in the absence of this factor) the protease did 
not sediment with the myofibrils. Therefore, the unknown 11 factor 11 
played a role in the binding of the protease to the myofibrillar proteins, 
but once the protease was bound the factor could be removed without 
affecting the binding of the protease . This factor was apparently 
solubilised upon exposure to 20 mM sodium pyrophosphate, since removal 
of this supernatant allowed the myofibrillar proteins and the alkaline 
protease to be separated. 
The isolated protease was found to be sensitive to chymostatin as only 
5% of activity (relatively to a control) remained in the presence of 
6,6 µg/ml of chymostatin. The protease isolated by Katunuma et al. 
(1975) was also sensitive to chymostatin, 50% activity remaining at 
0,023 µg/ml of the inhibitor. The protease was, however, different 
from that isolated by Dahlmann and Reinauer (1978) which showed 89% 
of its activity at a chymostatin concentration of 10 µg/ml. In the 
presence of 10 µg/ml soybean trypsin inhibitor, 67% of the activity 
was unaffected. This protease is thus less sensitive to soybean 
trypsin inhibitor than the protease isolated by Katunuma et al (1975), 
which had only 50% of its maximum activity in the presence of 6,3 µg/ml 
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soybean trypsin inhibitor. The protease of Griffin and Wildenthal 
(1978) had less than 10% activity with 25 µg/ml inhibitor, while 
that of Murakami and Uchida (1978) retained 26% activity in the 
presence of 100 µg/ml soybean trypsin inhibitor. A pepstatin con-
centration of 5 µg/ml had no effect on the purified proteolytic · 
activity, whilst the protease of Katunuma et al (1975) was described 
as having 50% activity at a pepstatin concentration which was greater 
than the 200 µg/ml tested in that study. ·Leupeptin at a concentra-
tion of 10 µg/ml had no effect on the protease activity, while at the 
same inhibitor concentration the protease of Dahlmann and Reinauer 
(1978) only showed 73% of its activity. The protease isolated by 
me did not require Ca+2 or other divalent metal ions, since 90% of 
its activity was still evident in the presence of 2 mM EGTA. As 
neither leupeptin nor pepstatin affected the proteolytic activity, 
it can be concluded that the protease is not cathepsin B or cathepsin 
D. However, chymostatin was a potent inhibitor of proteolytic activity 
and thus it can be concluded that the protease was a 11 chymotrypsin-like 
pro~ease 11 • 
The preliminary study of rats treated with· compound 48/80 was found 
to be ambiguous in that a reproducible reaction by the rats could not· 
be obtained. In some cases the rats died from the injections, while 
in others the degranulation was found to be incomplete. However, it 
would appear from the results that chymostatin-sensitive MAP is present 
in compound 48/80-treated rats. Cl~arly, further research is required 
to standardise the treatment to exclude the possibility that the alka-
line protease activity detected was not due to residual mast cell 
granules due to incomplete degranulation by compound -48/80. Ideally 
the alkaline protease should be purified to homogeneity from proven 
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granule-free skeletal muscle and then compared to the MAP which I have 
purified. In this way the possible mast cell origin of the protease 
will be elucidated. 
With the same purification procedure (up to the washed myofibrillar step) 
I have shown the presence of a similar protease in rat cardiac muscle. 
This protease is therefore clearly different from the protease purified 
by Banno et al (1975), since their protease was not detected in cardiac 
muscle. 
The results presented here show that the protease isolated by me is 
different from the reported proteases of other researchers and thus it 
must be concluded that this myofibrillar alkaline protease is a differ-
ent entity. It does, however, show degrees of similarity with a 
number of previously isolated alkaline proteases. As the protease may 
theoretically play an important role in protein-catabolism and as the 
presence of a physiological inhibitor has been demonstrated, it must be 
assumed that this myofibrillar alkaline protease is capable of playing 
an important regulatory role. Further study is thus warranted to 
help to establish whether the newly isolated enzyme is a true muscle-




MATERIALS AND METHODS 
4.1. MATERIALS 
All operations were carried out at 4°C unless otherwise stated. 
Water double-distilled in glass was used for all solutions. 
Centrifugation was performed in a Beckman Model J 21-C centrifuge, 
except for the ultracentrif_ugation where a Beckman Model L 5-65 ultra-
centrifuge was used, and for the enzyme assays and CM-Sephadex C-50 
batch steps where a Mistral 6L centrifuge was used. 
Homogenisation was done with . an Ultra-Turrax homogeniser. 
Sephadex G-75 and CM-Sephadex C-50 were purchased from Pharmacia 
(Uppsala, Sweden). When not in use, columns of Sephadex G-75 wer~ 
stored in the presence of sodium azide to prevent microbial growth. 
Fresh CM-Sephadex C-50 columns were prepared each time. 
Leupeptin and chymostatin were purchased from the Peptide Institute 
(Osaka, Japan). Pepstatin and soybean trypsin inhibitor were obtained 
from Sigma (USA). Dithiothreitol, cytochrome C and bovine serum 
albumin (fraction V) were purchased from Miles (Cape Town). Tris base, 
EDTA and Na4P2o7 were purchased from Merck (Germany). 
Standards for gel electrophoresis and concentrated dye reagent for 
protein determination were obtained from BIO-RAD Laboratories (California). 
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All chemicals not further described were of 11 Analar 11 grade, or equi-
valent thereof, supplied by various companies. 
4.2. MYOFIBRILLAR ALKALINE PROTEASE ASSAYS 
4.2.1. Denatured casein substrate methods 
4.2.1.1. Preparation of denatured casein 
Denatured casein was prepared as follows: 2,5 gram casein was added 
·to 10 ml of 500 mM Tris-HCl, pH 7,4 and the mixture pre-incubated at 
37°c for 20 min, after which 0,75 ml of 2 M NaOH was added. After 
heating in a boiling waterbath for 20 min, the solution was cooled and 
the volume made up to 50 ml with 500 mM Tris-HCl, pH 7,4. The solution 
was then dialysed overnight against 10 vol. of the same buffer and the 
pH adjusted to 7,4. 
4.2.1.2. Conditions of assay 
The samples were prepared in sets of four, one for each time point. 
The assay incubation mixture_ contained the following: 1,1 ml of 1,2 M 
KCl - 0, 1 M -glycine - NaOH buffer, pH 9 ,0 and l 00 l-11 denatured casein 
in 500 mM Tris-HCl buffer, pH 7,4. The reaction was initiated by the 
addition of 300 µ1 of the enzyme fraction. The mixture was incubated 
at 37°c. The reaction was terminated at 0, 15, 30 and 45 min. by the 
addition of TCA. Using the tyrosine-release method, 1,5 ml of 20% TCA 
was added, whilst for the TCA-supernatant A-280 method 0,5 ml of 20% 
TCA was added. All the samples were kept in the waterbath at 37°C 
for 60 min. The samples were then placed at 4°c for 15 min. The 
sample was then mixed well and then centrifuged at 800 g for 10 min. 
7.1 
The supernatants were then treated as described below. 
4.2.1.3. Measurement of tyrosine release 
The tyrosine content of supernatants was measured fluorimetrically 
using the method of Waalkes and Udenfriend (1957). 1 ,0 ml of 0,1 % 
l-nitroso-2-naphthol in 96% ethanol was added to 2,0 ml of TCA-super-
natant containing released tyrosine. The solution was mixed and 1,0 ml 
of 0,05% sodium nitrite in nitr.ic acid (diluted 5 times) was added. 
After mixing, the tubes were stoppered, incubated at 55°c for 30 min 
and then cooled. The unreacted substrate was extracted with 9 ml 
1,2-dichloroethane. The. tubes were shaken well and centrifuged briefly 
at 200 g to separate the aqueous and the organic layers. The fluores-
cence of the upper, aqueous layer was measured on a Perkin-Elmer fluores-
cence spectrophotometer (Aex = 460 nm; Aem = 570 nm). Tyrosine 
(0 - 20 nmoles) was used as a standard. Each time point was prepared 
in duplicate. 
release. 
Enzyme activity was determined by the rate of tyrosine 
4.2.1.4. Measurement of TCA-supernatant A-280 . 
The aromatic amino acid content of TCA-supernatants was determined by 
measuring their absorbance at 280 nm in a Unicam SP1800 UV spectro-
photometer. Each time point was measured in duplicate and the O min 
time point was used as the blank. 
the rate of increase of A280. 
Enzyme activity was determined by 
4.2.2. l125 rl...:1abelled casein as substrate 
4.2 .2.1 . Preparation of j1 25 r!-labelled casein 
I 125 rl -labelled casein was prepared according to a modified method of 
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Hunter and Greenwood (1962). All solutions used were prepared in 
0,05 M sodium phosphate buffer, pH 7,5. To 5 µl of 1125 11 (0,5 mCi) 
was added 1 ,0 ml of casein (2,5%). 250 µ1 chloramine T (4%) was then 
added and the mixture was allowed to stand at 4°C for 5 min. After 
the addition of 250 µ1 5% sodium metabisulphite, the mixture was slowly 
applied to a Sephadex G-75 column (0,9 x 30 cm), previously equilibrated 
with the same buffer and the sample washed with 3 sample volumes of 10% 
potassium iodide in water. The sample was eluted with the same buffer 
at a flow rate of 6 ml/hand 1 ,0 ml fractions were collected. Aliquots 
were counted in a Nuclear Enterprise 8312 gamma counter. 112511-
labelled casein eluted with the void volume and the unreacted 1125 11 
eluted at a later stage. The l1251l-1abelled casein peak was pooled 
and dialysed overnight against 10 vol of 0,05 M sodium phosphate buffer, 
ptt 7,5. 
4.2.2.2. Conditions of assay 
The samples were prepared in duplicate sets of four. · The enzyme activity 
was assayed as described in 4.2.1.2., except that 20 µ1 of 11251!-
labelled casein and 80 µl of denatured casein were used as substrate 
instead of 100 µl denatured casein. The reaction was stopped at 0, 15, 
30 and 45 min by the addition of 0,5 ml 20% TCA. 
4.2.2.3. Measurement of TCA-soluble radioactivity 
Aliquots of 50 µ1 were removed from an incubation mixture containing · 
buffer instead of enzyme and were counted directly to obtain the total 
radioactivity. TCA-soluble radioactivity was measured using the gamma-
counter (as in 4.2.2.1 .) on duplicate samples for each assay tube. 
Zero time radioactivity was taken as background cpm and the cpm thus 
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obtained were subtracted from the sample cpm. Enzyme activity was 
determined by the rate of increase of TCA-soluble radioactivity. 
4.2.3. Azocasein as substrate 
The samples were prepared in duplicate sets of four. The assay mixture 
containing 250 µl of 5 mg/ml azocasein dissolved in 1 ,2 M KCl - 0,1 M 
glycine - NaOH buffer, pH 9,0 to which 250 µl of enzyme solution was 
added to initiate the reaction. The incubation was carried out in a 
waterbath at 37°C. The reaction was stopped at 0, 15, 30 and 45 min 
by the addition of 0,5 ml 4% TCA. All samples were kept in the water-
bath for a total of 60 min. The samples were then removed and kept at 
4°C for 15 min. The samples were then mixed well and then centrifuged 
at 1 500 g for 10 min at 4°C. The absorbance of the yellow TCA-soluble 
fraction was then measured at 340 nm. 
4.3. PROTEIN DETERMINATION 
The protein concentration of samples was measured according to the 
method of Bradford (1976), using the colour reagent obtained from Bio-
Rad Laboratories. Sephadex G-75 fractions (2.2.2.9) were assayed on 
the basis of their A220 readings relative to bovine serum albumin. 
4.4. ISOLATION AND PURIFICATION OF MAP 
4.4.l. Sample preparation 
Fed male rats (~ 250 gram) were killed by cervical dislocation and the 
hind limb muscles were immediately removed and placed in a chilled 
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solution of 0,1 M KCl - 2 mM MgCl 2 - 2 mM EGTA - 2 mM Na4P2o7 - 10 mM 
Tris - Maleate buffer, pH 7,1 (pyrophosphate-enriched low salt buffer). 
The rat skeletal muscle was then trimmed of excess fat and connective 
tissue, cut into small pieces and homogenised in 10 vol (v/m) of 
fresh pyrophosphate-enriched low salt buffer. 
4.4.2. Washed myofibril preparation 
The homogenate was then centrifuged at 800 g for 10 min at 4°C. The 
precipitate was retained and resuspended in pyrophosphate-enriched LSB. 
The suspension was then centrifuged as described for the homogenate. 
The resulting precipitate was then treated in the same way for a further 
two washes with pyrophosphate-enriched LSB. Thereafter, the precipitate 
was suspended in 5 vol of pyrophosphate-enriched LSB containing 1% Triton 
X-100. This suspension was then centrifuged as before. This precipi-
tate was subjected to a further two washes with pyrophosphate-enriched 
LSB. The final precipitate obtained was called the washed myofibril 
fraction. 
4.4.3. Wash at a high concentration of pyrophosphate 
The washed myofibril fraction was suspended in 10 vol of fresh 20 mM 
tetra-sodium pyrophosphate. The suspension was stirred at 4°C for 1 
hour. The resulting mixture was then centrifuged at 8 000 g for 30 
minutes at 4°C. The supernatant was discarded whilst the precipitate 
was retained as the pyrophosphate-wash precipitate. 
4.4.4. Solubilisation at high salt concentration 
The pyrophosphate-wash precipitate was then placed in 10 vol of 0,6 M 
potassium chloride and stirred at 4°C for 1 hour. The mixture was 
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then centrifuged at 48 000 g for 30 min at 4°c. 
decanted and retained. 
I 
The supernatant was 
4.4.5. Dialysis of KCl-supernatant 
The high salt supernatant was then dialysed using Thomas (1 ,5875 cm) 
dialysis tubing which had been boiled in a solution containing traces 
of potassium bicarbonate and sodium EDTA. The supernatant was dialysed, 
against 10 vol of 0,1 mM OTT - 5 mM potassium phosphate buffer, pH 8,5, 
at 4°C overnight. The equilibrated dialysate was then centrifuged at 
48 000 g at 4°C for 15 minutes. The supernatant was retained as the 
dialysed supernatant. 
4.4.6. CM-Sephadex C-50 batch step 
The dialysed supernatant was stirred at 4°C in the presence of pre-
equilibrated CM-Sephadex C-50 for 30 minutes. The CM-Sephadex C-50 
had been equilibrated with 3 x 10 min washes with 10 mM Tris-HCl buffer, 
pH 6,0. The excess buffer was decanted following each wash. The 
CM-Sephadex C-50 equilibration was performed at room temperature. The 
suspension was then centrifuged at 1 500 g for 1 min at 4°c. 
The CM-Sephadex C-50 sediment, containing bound-protein, was then stirred 
with 10 vol of 0,7 M KCl - 10 mM Tris-HCl buffer, pH 6,0.for 30 min at 
4°c. The suspension was again centrifuged at 1 500 g for 1 min at 4°c. 
The resulting CM-Sephadex C-50 sediment was stirred with 5 vol of 
1 ,5 M KCl - 10 mM Tris-HCl buffer, pH 6,0 for 30 min at 4°c. This sus-
pension was then centrifuged at 4°C for 1 min at 1 500 g. The super-
natant, in this case, was decanted and retained. The supernatant was 
then dialysed overnight at 4°C against 10 vol of 0,1 mM OTT - 5 mM 
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potassium phosphate buffer, pH 8,5. 
4.4.7. Ultrafiltration 
The CM-1 ,5 M dialysed supernatant was then filtered at 4°c, under a 
positive pressure of 4,5 bar (under high purity nitrogen) in an Amicon 
ultrafiltration Cell Model 52 fitted with a PM-10 membrane. The super-
natant was concentrated by approximately 3-fold by means of ultra-
filtration. 
4.4.8. Sephadex C-50 column chromatography 
The resulting solution from the ultrafiltration step was applied to an 
equilibrated CM-Sephadex C-50 column (1 ,4 x 5,5 cm). The resin was 
equilibrated as in 4.4.6. and then poured into the column at 4°C; 
250 ml 10 mM Tris-HCl buffer, pH 6,0, was then passed through the column 
under standard conditions before the enzyme sample was applied. The 
column was eluted -at 4°c at a flow rate of 10 ml/hand 3,125 ml fractions 
were collected. The sample was eluted under these standard conditions 
by a linear salt gradient (0 M NaCl+ 0,7 M NaCl) in 10 mM Tris-HCl 
buffer, pH 6,0. The enzyme peak was pooled and dialysed overnight 
against 10 vol of 0,1 mM OTT - 5 mM potassium phosphate buffer, pH 8,5. 
The dialysate was then concentrated by vacuum dialysis at 4°C to a final 
volume of 3 ml. 
4.4.9. Sephadex G-75 chromatography 
The 3 ml concentrated enzyme was placed on an equilibrated G-75 column 
(1 ,6 x 90 cm) at 4°C. The column had been equilibrated with 250 ml 
0,6 M KCl - 10 mM Tris-HCl buffer, pH 7,0 passed through the column 
under standard conditions. The sample was then eluted with the same 
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buffer at a flow rate of 10 ml/hr. Elution fractions of 2,5 ml were 
collected. 
4.4.10. Treatment of rats with Compound 48/80 
Rats were treated with Compound 48/80 according to the method of Riley 
(1959). Rats (150 g) were injected intraperitoneally, daily over five 
days, with compound 48/80. Each rat received 100 µg/100 g on day 1, 
200 on day 2, 300 on day 3, 400 on day 4 and 500 on day 5. The animals 
were killed on day 6 by cervical dislocation and the muscles were quickly 
removed. 
4.5. POLYACRYLAMIDE GEL ELECTROPHORESIS 
4.5.l. SDS-Polyacrylamide gel electrophoresis 
SDS-polyacrylamide gel electrophoresis was performed on 15 - 8% acryl-
amide slab gels according to a mod i fied method of Laemmli (1970). The 
two gel solutions were poured into a gradient maker so as to give a 15% 
to 8% linear acrylamide gradient. The two solutions contained the f o 11 owing: 
8% acryl amide 15% acryl amide 
0, l % SDS 0,1 % SDS 
5% (v/v) glycerol 10% (v/v) glycerol 
0,37 M Tris-HCl, pH 8,8 0,28 M Tris-HCl, pH 8,8. 
The gels were polymerised chemically by the addition of ammonium per-
sulphate and N,N,N' ,N'-tetramethylethylenediamine (TEMED) to a final 
concentration of 0,03% (m/v) and 0,025% (v/v), respectively. The 
stacking gel contained 5% acrylamide, 0,1 % SDS and 0,1 M Tris-HCl, 
pH 8,8 and was polymerised by the addition of 0,05% (v/v) TEMED and 
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0,1 % (m/v) ammonium persulphate. The electrode buffer consisted of 
0,025 M Tris-HCl, 0,19 M glycine and 0,1 % SOS, pH 8,8. 
Protein samples were dissolved in a sample buffer consisting of 2% SOS, 
10% (v/v) glycerol, 5% (v/v) 2-mercaptoethanol and 0,05 M Tris-HCl, 
pH 6,8 and boiled for 2 min. Electrophoresis was carried out for 3,5 h 
at a constant current of 25 mA. Gels were fixed and stained overnight 
in 200 ml of 0,025% Coomassie blue, 25% isopropyl alcohol and 10%- acetic 
acid. Gels were destained with shaking . in 10% acetic acid. 
4.-5.2. Gelatin polyacrylamide gel electrophoresis 
Gelatin PAGE was performed on a 0,1 % gelatin - 11 % polyacrylamide slab 
gel. The running gel solution contained the following: 
11 % A-bis A (30:l = acrylamide:bis acrylamide (m/m)) 
0,375 M Tris-HCl buffer, pH 8,0 
0, 1 % sos 
0,1 % gelatin. 
The gel was polymerised chemically by the addition of arrrnonium persul-
phate and TEMEO to a final concentration of 0,02% (m/v) and 0,11 % (v/v), 
respectively. The stacking gel contained 10% A-bis A, 0,05% SOS and 
0,0625 M Tris-HCl buffer, pH 6,8 and was polymerised by the addition of 
0,25% (v/v) TEMEO and 0,05% (v/v) ammonium persulphate. All the gel 
solutions were autoclaved and kept sterile prior to use. The electrode 
buffer consisted of 0,19 M glycine - 0,1 % SOS - 0,025 M Tris-HCl buffer, 
pH 8,8. 
The enzyme sample was dialysed against a 0,1 mM OTT - 5 mM potassium 
phosphate buffer, pH 8,5. SOS and sucrose were added to the enzyme 
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sample to give a final concentration of 2,5% (m/v) and 8% (m/v), respec-
tively. The sample was then incubated at 37°c for 30 minutes. 
Electrophoresis was done at 4°c at a constant current of 0,8 mA, while 
the sample was in the stacking gel and then adjusted to 0,6 mA. The 
voltage was not allowed to exceed 100 V. 
for 3,5 h. 
Electrophoresis was continued 
After electrophoresis, the gel was washed in 2,5% Triton X-100 for l h 
with shaking. The gel was then rinsed quickly under distilled water 
and then placed into warm l ,2 M potassium chloride - 0,1 M glycine -
NaOH buffer, pH 9,0. 
3 h. 
Incubation was done at 37°C with shaking for 
After incubation, the gels were stained overnight in 0,1 % Amido black. 
Gels were then destained with shaking in 101 acetic acid until clear 
lysis bands could be observed. 
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